NCT00633269View on ClinicalTrials.gov

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Neoplasm Metastasis
Interventions
DRUG

AZD2281

100mg Oral Dose

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

KuDOS Pharmaceuticals Limited

INDUSTRY

lead

AstraZeneca

INDUSTRY